Search

Your search keyword '"Fregoni V"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Fregoni V" Remove constraint Author: "Fregoni V"
84 results on '"Fregoni V"'

Search Results

1. OC 29.1 Long-Term Outcomes of COVID-19 Associated Venous Thromboembolism (VTE)

2. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

4. Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials

5. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma

6. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

7. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma

8. Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials

11. P01.067 Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma: the experience of the Italian Association of Neuro-Oncology

12. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer

16. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

17. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

18. Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi

25. Prognostic relevance of serum 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study

26. Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies

27. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.

28. Paclitaxel in anthracycline-treated breast cancer patients.

31. Reduced and delayed incidence of human cytomegalovirus infection following non-myeloablative allogeneic stem cell transplantation in patients with refractory solid tumours

41. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III trials

42. Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies

43. EX VIVO GENERATION AND EXPANSION OF ANTI-TUMOR CYTOTOXIC T-CELL LINES DERIVED FROM PATIENTS OR THEIR HLA-IDENTICAL SIBLING

44. Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.

45. Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes.

46. Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register.

48. Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study.

49. Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

50. Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.

Catalog

Books, media, physical & digital resources